Login to Your Account



Other News To Note


Thursday, July 11, 2013
• Pharmacyclics Inc., of Sunnyvale, Calif., and Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said a new drug application was submitted for ibrutinib for use in previously treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia and for use in previously treated patients with mantle cell lymphoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription